Quest PharmaTech Announces Opposition to OQPBIOM's Acquisition of AdBioTech

Core Viewpoint - Quest PharmaTech Inc. opposes the acquisition of a controlling interest in AdBioTech by OQPBIOM Inc. and was not consulted prior to this decision, raising concerns about the implications for funding and the advancement of its immunotherapy assets [1][3]. Group 1: Company Background - Quest PharmaTech Inc. is a Canadian biopharmaceutical company focused on developing products to enhance quality of life [4]. - The company holds a 42.5% ownership interest in OncoQuest Inc. and a 23% ownership interest in OncoVent, which is involved in developing antibody-based immunotherapeutic products for cancer [4]. - Quest is also developing proprietary MAb AR 9.6, which targets truncated MUC16 as theranostic agents for cancer and is currently in the late preclinical stage [4]. Group 2: Recent Developments - As of June 2, 2025, Quest acquired a 26.25% share ownership interest in OQPBIOM Inc., becoming its largest shareholder [2]. - OQPBIOM Inc. was established to conduct clinical trials for oregovomab, a novel ovarian cancer drug candidate developed by OncoQuest Inc. [2]. - Quest's CEO, Dr. Madi Madiyalakan, expressed that the company was not informed about OQM's acquisition strategy and believes it is not in the best interest of OQM or its shareholders [3].